Europe’s medicines watchdog has been told it can appeal against a High Court ruling that said the UK’s exit from the European Union does not give it the right to walk away from a £500m lease on its Canary Wharf office.

The decision looks set to reopen a case that had gripped property executives. Many had said an initial ruling in favour of the European Medicines Agency would have allowed swathes of office occupiers in London to break their leases without financial penalty, citing the upheaval of Brexit.